Targeted therapies in ER+ metastatic breast cancer patients
Cancer du sein: best of 2016
Barbara Pistilli
Gustave Roussy Cancer Center
Paris, 3 Décembre 2016
Mon Plan
EBC MBC
ER
+
HER2+
TN
the best of 2016
Mon Plan
EBC MBC
ER
+
HER2+
TN
the best of 2016
Long-term recurrence risks after use
of endocrine therapy for only 5 years
Relevance of breast tumour characteristics
Hongchao Pan, Richard Gray, Christina Davies, Richard Peto,
Jonas Bergh, Kathleen I Pritchard, Mitch Dowsett, Daniel F Hayes,
for the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
1
/
47
100%
